导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.18% | 2110/4773 |
| 近一周 | -2.39% | 3805/5465 |
| 近一月 | -6.14% | 4056/5421 |
| 近一季 | -13.08% | 4099/5231 |
| 近半年 | -1.62% | 1838/4920 |
| 近一年 | 4.07% | 1929/4394 |
| 近两年 | 60.95% | 1211/2954 |
| 近三年 | 32.20% | 1012/2253 |
| 成立以来 | 171.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.81% 1975/4961 |
20.27% 1242/5312 |
- - |
- - |
| 2025 | 27.49% 1553/4813 |
1.09% 1705/3635 |
-0.54% 2957/4076 |
27.86% 1294/4524 |
-0.83% 2665/4813 |
| 2024 | 9.62% 1456/3463 |
-0.69% 1138/2808 |
-3.28% 1332/3014 |
18.17% 1047/3129 |
-3.42% 2343/3463 |
| 2023 | -9.85% 1238/2656 |
6.11% 725/2280 |
-3.59% 840/2385 |
-6.25% 1461/2515 |
-6.00% 1588/2655 |
| 2022 | -23.58% 1151/2207 |
-17.59% 1224/1919 |
8.14% 385/2016 |
-16.13% 1405/2113 |
2.25% 1004/2208 |
| 2021 | 1.73% 655/1822 |
-4.83% 889/1255 |
11.45% 374/1330 |
-6.52% 945/1466 |
2.59% 559/1822 |
| 2020 | 49.50% 177/1250 |
-5.04% 396/1028 |
22.77% 198/1067 |
12.33% 394/1164 |
14.16% 295/1184 |
| 2019 | 46.23% 139/1092 |
31.63% 196/754 |
-1.95% 338/804 |
3.14% 266/850 |
9.84% 184/918 |
| 2018 | -30.80% 478/834 |
- - |
- - |
- - |
-15.02% 597/691 |
| 2017 | 30.79% 55/714 |
- - |
- - |
- - |
- - |
| 2016 | -13.40% 322/605 |
- - |
- - |
- - |
- - |
| 2015 | 30.15% 76/575 |
- - |
- - |
- - |
- - |
| 2014 | 37.77% 137/237 |
- - |
- - |
- - |
- - |
| 2013 | -1.65% 68/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信深证100指数增强 VS. 长安沪深300非周期A(740101) |